The US Food and Drug Administration (FDA) has posted a Warning Letter to Ipca Laboratories for violations of current good manufacturing practices (cGMP) based on inspections of three facilities of the company in India made in 2014 for data integrity issues. The violations were noted at the company's active pharmaceutical ingredient (API) manufacturing facility in Ratlam, Madhya Pradesh based on a inspection conducted July 14-18, 2014 and at two manufacturing facilities for finished pharmaceuticals in Pithampur, Madhya Pradesh based on an inspection in October 13-17, 2014 and at facility in Piparia Silvassa Union Territory of Dadra & Nagar Haveli based on an inspection made December 1-19, 2014. The FDA reviewed the firm's responses of August 8 and November 7, 2014, and January 9, 2015 with respect to these facilities. The FDA said that it observed systemic data manipulation and other cGMP violations and deviations at the three sites.